| Bioactivity | Tyrosine kinase-IN-7 (compound 13h) is an inhibitor of the tyrosine kinase EGFR. The IC50s for inhibiting EGFR(WT) and EGFR(T790M) are 0.630 μM and 0.956 μM respectively. Tyrosine kinase-IN-7 has antitumor activity against four cancer cell lines (HepG2, HCT-116, MCF-7, and A431) with IC50s of 13.02 μM, 10.14 μM, 12.68 μM, and 47.05 μM, respectively[1]. |
| Target | IC50: 0.630 μM (EGFRWT), 0.956 μM (EGFRT790M) |
| Name | Tyrosine kinase-IN-7 |
| CAS | 345615-74-9 |
| Formula | C16H15N3OS |
| Molar Mass | 297.37 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Elmetwally SA, et al. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers. Bioorg Chem. 2019 Jul;88:102944. |
Tyrosine kinase-IN-7
CAS: 345615-74-9 F: C16H15N3OS W: 297.37
Tyrosine kinase-IN-7 (compound 13h) is an inhibitor of the tyrosine kinase EGFR. The IC50s for inhibiting EGFR(WT) and E
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.